

RADIOMOLECULAR PRECISION ONCOLOGY
FOR PATIENTS WORLDWIDE
THE ICPO FOUNDATION.

ICPO THERANOSTICS VIRTUAL SUMMIT

NOV 12 & 13, 2026 - PROGRAM

CHAIRS



Prof. Richard P. Baum



Prof. Frederik L. Giesel



Prof. Rudolf A. Werner

MODERATORS



Odile Jaume
CEO



Susanne Simon
Head of Communications

Interact Live with the Chairs From the ICPO Studio and Grow Your Knowledge Regarding:

- Rising Stars in Theranostics
- Growing Space of Alphas
- Clinical Trials Planning
- Leveraging AI in Theranostics Globally
- Recommendations to Grow Patient Access Over the Next 5 Years

REGISTER HERE:

With support from:

NOVARTIS

itm PASSION FOR PRECISION
tpi TerraPower Isotopes
SOFIE From start to clinic
AdvanCell
PERSPECTIVE THERAPEUTICS
SHINE
SIEMENS Healthineers
Telix
oncoBeta®
PANTERA A BETTER FIGHT FOR LIFE

WWW.ICPO.FOUNDATION

ICPO THERANOSTICS VIRTUAL SUMMIT

ADOPTING NEW RADIOPHARMACEUTICALS AT YOUR THERANOSTICS CENTER

DAY 1: NOV 12, 2026 – CET TIME ZONE

Welcome by the Chairman and CEO of the ICPO Foundation followed by the Summit Chairs
2:00 - 2:15 pm


Udo J. Vetter


Odile Jaume


Richard P. Baum


Frederik L. Giesel


Rudolf A. Werner

KEYNOTE: From Imaging to Cure: Theranostics as a Core Pillar in Today's Oncology, 2:15 - 2:35 pm


Michael Hofman

SESSION I: Outlook into Next Gen Emitters
2:35 - 3:25 pm


Reminiscence of Y90 DOTATOC for NET
Richard P. Baum


Selection of the optimal Radionuclide: Efficacy and Safety of Tb161 versus Lu177
Cristina Mueller


Clinical Potential of Tb161 for Radioligand Therapy
Damian Wild

SESSION II: Clinical Trends in Alpha Corner
3:25 - 4:25 pm


Ac225 Insights in Latest Trials
Mike Sathekge


Latest Clinical Advances in Astatine (At211)
Tadashi Watabe


Novel Development and Dosing Strategies for Alpha Therapies, ADVC001 (Pb212) Experience
Anna Karmann


Pb212 Beyond Prostate Cancer
Michael Schultz

PANEL 1: Alpha Only Approach: Potential & Effectiveness? Benchmark with Combination Therapies?
4:30 - 4:55 pm

Moderators


Richard P. Baum


Frederik L. Giesel

Panelists


Ebrahim Delpassand


Cristina Müller


Mike Sathekge


Tadashi Watabe

BREAK: 4:55 5:05 pm

ICPO THERANOSTICS VIRTUAL SUMMIT

ADOPTING NEW RADIOPHARMACEUTICALS AT YOUR THERANOSTICS CENTER

DAY 1: NOV 12, 2026 – CET TIME ZONE

SESSION III: Sunrise of FAP & Other Compounds on the Horizon
5:05 - 5:55 pm



FAP-based Radiotheranostics for the Treatment of Diverse Adenocarcinomas and Sarcomas
Elisabetta Perrone



3rd Generation of PSMA
Steven Rowe



Novel Targets incl. CAIX, PL1 and Others
Masato Murakami

SESSION IV: Will "Big" or "Small" Shape The Future? What Space for Pre-Targeting?
5:55 - 6:40 pm



Perspective from Radiopharmaceutical Innovation
Jens Cardinale



Perspective from Clinical Radiochemistry
Jason Lewis



Perspective from Translational Nuclear Medicine
Susanne Lütje

PANEL 2: Is FAP Revolutionary in Terms of Patient Outcomes? Will it Become the New Gold Standard for All Theranostics Centers?
6:45 - 7:10 pm

Moderators



Frederik L. Giesel



Rudolf A. Werner

Panelists



Jason Lewis



Sherly Mosessian



Masato Murakami



Steven Rowe

Wrap Up and Closing of Day 1: Impressions from Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner
Closing - Odile Jaume & Susanne Simon
7:10 - 7:15 pm



Richard P. Baum



Frederik L. Giesel



Rudolf A. Werner



Odile Jaume



Susanne Simon

ICPO THERANOSTICS VIRTUAL SUMMIT

PLANNING AND NAVIGATING CLINICAL TRIALS AT YOUR THERANOSTICS CENTER

DAY 2: NOV 13, 2026 – CET TIME ZONE

WELCOME By the CEO of the ICPO FOUNDATION
10:00 - 10:05 am



Odile Jaume

KEYNOTE: Future Outlook Into Radiotheranostics
10:05 - 10:25 am



Ken Herrmann

SESSION V: Planning Your Clinical Trial
10:25 - 11:15 am



Current and Future Design of Theranostics Clinical Trials
Igor Rakovic



Structuring & Managing Trial Data
Sam Vohra



Listening to Patients Advocates on Clinical Trials
Erik Briers

SESSION VI: Navigating Trial Design Involving Novel Approaches: 11:15 - 12:00 pm



First Use of Re188-PSMA, as Tc99m-PSMA Companion:
Mike Sathekge



uPAR-targeted PET Imaging Tracers in Oncology Research – Andreas Kjaer



Role of Genomics & Transcriptomics or when in Vitro Meets in Vivo
Ralph Wirtz

PANEL 3: Highlights of a PRRT Patient Journey and Lessons Learned
12:00 - 12:25 pm

Moderator



Rudolf A. Werner

Panelists



Tiphaine Locqueneux



Meredith Cummins



Ken Herrmann

BREAK: 12:25 - 12:35 pm

ICPO THERANOSTICS VIRTUAL SUMMIT

PLANNING AND NAVIGATING CLINICAL TRIALS AT YOUR THERANOSTICS CENTER

DAY 2: NOV 13, 2026 – CET TIME ZONE

SESSION VII: How To Reach And Select Patients For Your Trials?
12:35 - 1:25 pm



Theranostics Patient Selection at Large Volume Cancer Center
Désirée Deandreis



Challenges and Opportunities in Patient Recruitment for Theranostics in Emerging Research Centers
Cecilia Carreras



Leveraging Ancora.ai Radiopharmaceuticals Trial Finder
Danielle Ralic

SESSION VIII: Leveraging AI In Theranostics At Your Center
1:25-2:15 pm



Leveraging AI to Advance Clinical Theranostics Globally
Johannes Tran-Gia



Empowering AI in Clinical Trials
Vikas Prasad



ARCHE: An AI-driven Curation and Harmonization Engine for Structuring Multimodal Theranostics Data
Lalith Sundar

PANEL 4 / FINAL ROUND TABLE: Essential Recommendations to Grow Patient Access to Radiotheranostics Innovation Over the Next 5 Years?
2:15 - 2:40 pm

Moderators



Richard P. Baum



Frederik L. Giesel



Rudolf A. Werner

Panelists



Akram Al-Ibraheem



Désirée Deandreis



Vikas Prasad

Wrap up of ICPO Summit 2026 by the Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner. Closing by Odile Jaume and Susanne Simon
2:40 - 3:00 pm



Richard P . Baum



Frederik L. Giesel



Rudolf A. Werner



Odile Jaume



Susanne Simon

THANK YOU FOR YOUR ATTENTION
CONTACT ICPO FOUNDATION: INFO@ICPO.FOUNDATION